Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.175
-0.045 (-3.69%)
Streaming Delayed Price
Updated: 10:34 AM EDT, Oct 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
May 09, 2023
Via
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
May 08, 2023
Via
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
Via
ACCESSWIRE
Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi
May 01, 2023
Via
ACCESSWIRE
U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care
April 27, 2023
Via
ACCESSWIRE
Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
April 11, 2023
Via
ACCESSWIRE
Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million
March 27, 2023
Via
ACCESSWIRE
Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT
March 24, 2023
Via
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
March 21, 2023
Via
ACCESSWIRE
Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug
March 13, 2023
Via
ACCESSWIRE
Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling
April 06, 2023
Via
ACCESSWIRE
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
March 30, 2023
Via
ACCESSWIRE
Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board
March 23, 2023
Via
ACCESSWIRE
Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities
March 15, 2023
Via
ACCESSWIRE
Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases
March 02, 2023
Via
ACCESSWIRE
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
February 23, 2023
Via
ACCESSWIRE
Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
February 09, 2023
Via
ACCESSWIRE
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
February 08, 2023
Via
ACCESSWIRE
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
February 28, 2023
Via
ACCESSWIRE
Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
February 21, 2023
Via
ACCESSWIRE
Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
February 01, 2023
Via
ACCESSWIRE
Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling
February 01, 2023
Via
ACCESSWIRE
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
January 30, 2023
Via
ACCESSWIRE
Jaguar Health Reports Voting Results from January 2023 Special Meeting of Stockholders
January 20, 2023
Via
ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 27, 2023
Via
ACCESSWIRE
Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
January 26, 2023
Via
ACCESSWIRE
Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
January 25, 2023
Via
ACCESSWIRE
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
January 23, 2023
Via
ACCESSWIRE
Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31st
January 20, 2023
Via
ACCESSWIRE
REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies
January 11, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.